Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BD111 for refractory herpetic viral keratitis
NCT04560790Phase 1Completed
- Sponsor
- Shanghai BDgene Therapeutics Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Gene Silencing, CRISPR-Cas9, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BD111 in Herpetic keratitis, sponsored by Shanghai BDgene Therapeutics Co., Ltd. Primary endpoints: Effective clearance of HSV-1 genome at 12 months, Rate of reblindness in participants with Refractory HSV Keratitis at 12 months and 1 more. Started Nov 2020; status: completed.
02
Drugs
BD111
03
Conditions
Herpetic keratitis
Beyond the preview
Go deeper on NCT04560790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560790.